EUVIMEDEUVIMED entdecken
Crossref

Expanding Patient Access to Buprenorphine for Opioid Use Disorder Through Pharmacist Independent Prescriptive Authority

Michelle D Colvard iD, Terri L Jorgenson iD, Veldana Alliu iD, Tera D Moore iD, Haley E Pals iD, Jacob D Baylis iD, Michael Tran iD, Roisin M Sabol iD, Adam J Gordon iD

Substance Use & Addiction Journal · 2026

DOI: 10.1177/29767342261467580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Substance Use & Addiction Journal, 2026. Verfasst von Michelle D Colvard und 8 weiteren Autor:innen. Beteiligte Einrichtung: VA Tennessee Valley Healthcare System, Nashville, TN, USA. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Pharmacists, Health Services Accessibility. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: national institute on drug abuse, u.s. department of veterans affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the United States, despite evidence that medication treatment for OUD (MOUD) improves outcomes, buprenorphine MOUD (B-MOUD) treatment rates remain suboptimal. The Mainstreaming Addiction Treatment (MAT) Act, passed in 2022, removed federal prescribing restrictions which allowed any health care provider, including pharmacists, with a DEA (Drug Enforcement Administration) registration to prescribe B-MOUD unless otherwise restricted by their state of licensure. As of March 2026, only 16 states allow pharmacists to obtain DEA licensure for controlled substance prescriptive authority. The SUPPORT for Patients and Communities Reauthorization Act of 2025 indicates that pharmacists may prescribe B-MOUD independently where state law allows and sends a signal for states to align in this practice. Pharmacists have demonstrated the ability to provide comprehensive medication management in OUD treatment with positive outcomes of increased access, cost savings, reduced physician burden, enhanced medication utilization and adherence, improved treatment retention, and high patient satisfaction. Since implementation of the MAT Act, DEA-registered pharmacists in the Department of Veterans Affairs Veterans Health Administration (VHA) have independently prescribed B-MOUD. Clinical Pharmacist Practitioners (CPPs) within VHA practice as members of the interprofessional team and have independent prescriptive authority under a scope of practice based on their qualifications and competencies. This commentary describes CPP independent B-MOUD prescribing within VHA as an effective practice that could model pharmacist care in other large health care systems. Benefits of this model include increased B-MOUD access and retention while maintaining high quality, team-based care and use of telehealth to expand access to underserved areas. Major limitations include state legislative barriers that restrict pharmacist-controlled substance and B-MOUD prescribing. We call for advancements to state practice laws that authorize controlled substance prescriptive authority for pharmacists and reimbursement for services which are essential to continue expanding CPP B-MOUD prescribing within and beyond the VHA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersPharmacistsHealth Services AccessibilityOpiate Substitution TreatmentNarcotic AntagonistsHumansUnited StatesNon-Medical Prescribing

Stichwörter der Autor:innen

VeteransVeterans Health Servicesbuprenorphineclinicalopioid-related disorderspharmacists

Substanzen

BuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • VA Tennessee Valley Healthcare System, Nashville, TN, USA.
  • Clinical Pharmacy Practice Office, Pharmacy Benefits Management, Veterans Health Administration, Department of Veterans Affairs, Washington, DC, USA.
  • Tomah VA Medical Center, Tomah, WI, USA.
  • Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
  • Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Center for Healthcare Evaluation, Research, and Promotion, VA Pittsburgh Health Care System, Pittsburgh, PA, USA.

ORCID-Profile: Michelle D Colvard, Terri L Jorgenson, Veldana Alliu, Tera D Moore, Haley E Pals, Jacob D Baylis, Michael Tran, Roisin M Sabol, Adam J Gordon

Förderung

  • national institute on drug abuse
  • u.s. department of veterans affairs

Zitieren

APA

Colvard, M. D., Jorgenson, T. L., Alliu, V., Moore, T. D., Pals, H. E., Baylis, J. D., Tran, M., Sabol, R. M., & Gordon, A. J. (2026). Expanding Patient Access to Buprenorphine for Opioid Use Disorder Through Pharmacist Independent Prescriptive Authority. Substance Use & Addiction Journal. https://doi.org/10.1177/29767342261467580

Vancouver

Colvard MD, Jorgenson TL, Alliu V, Moore TD, Pals HE, Baylis JD, et al. Expanding Patient Access to Buprenorphine for Opioid Use Disorder Through Pharmacist Independent Prescriptive Authority. Substance Use & Addiction Journal. 2026. doi:10.1177/29767342261467580

BibTeX
@article{Colvard2026,
  author = {Colvard, Michelle D and Jorgenson, Terri L and Alliu, Veldana and Moore, Tera D and Pals, Haley E and Baylis, Jacob D and Tran, Michael and Sabol, Roisin M and Gordon, Adam J},
  title = {Expanding Patient Access to Buprenorphine for Opioid Use Disorder Through Pharmacist Independent Prescriptive Authority},
  journal = {Substance Use & Addiction Journal},
  year = {2026},
  doi = {10.1177/29767342261467580}
}
Kostenlos starten →